FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition based on it for the treatment of a disease associated with the CRBN protein, its use for the preparation of a medicinal product for the treatment of a disease associated with the CRBN protein, as well as a method of treating a disease associated with the CRBN protein. In the general formula (I), n is selected from the group consisting of 0, 1 and 2; each R1 is independently selected from the group consisting of F, Cl, Br, OH, NH2, C1-6-alkyl, C3-6-cycloalkyl, C1-6-alkoxy, C1-6-alkylamino, C2-6-alkenyl, 
, -S(=O)2NH2, -NHS(=O)2-C1-6-alkyl, -N[S(=O)2-C1-6-alkyl]2, -NHC(=O)-C1-6-alkyl and -C(=O)NH2, where NH2, C1-6-alkyl, C1-6-alkoxy, , -S(=O)2NH2 and -C(=O)NH2 are optionally substituted with 1 or 2 Ra; ring A is selected from the group consisting of 5–6-membered heteroaryl, phenyl and 5–6-membered heterocycloalkenyl; ring B is selected from the group consisting of phenyl; each Ra is independently selected from the group consisting of F, Cl, Br, OH, NH2, C1-6-alkyl, C1-6-alkoxy, C1-6-alkylamino, -NHC(=O)-C1-6-alkyl, C3-6-cycloalkylamino, 4–6-membered heterocycloalkyl, 5–6-membered heterocycloalkylamino and 5–6-membered heterocycloalkyl substituted with one carbonyl, where NH2, C1-6-alkyl, C1-6-alkylamino, C3-6-cycloalkylamino, 4–6-membered heterocycloalkyl and 5–6-membered heterocycloalkylamino are optionally substituted with 1 or 2 R; each R is independently selected from the group consisting of C1-3-alkyl, C1-3-alkoxy, C3-5-cycloalkyl, -C(=O)-C1-3-alkyl, -C(=O) OC1-6-alkyl, -S(=O)2-C1-3-alkyl, 
and 
; each of 5–6-membered heteroaryl, 4–6-membered heterocycloalkyl, 5–6-membered heterocycloalkylamino and 5–6-membered heterocycloalkyl substituted with one carbonyl contains 1 or 2 heteroatoms or heteroatomic groups independently selected from the group consisting of -NH-, -O- and N.
EFFECT: obtaining tricyclic compounds affecting CRBN proteins.
20 cl, 3 dwg, 4 tbl, 84 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PDE4 INHIBITOR | 2017 |
|
RU2743126C2 |
| DERIVATIVE WITH CONDENSED RING AS A RECEPTOR INHIBITOR | 2018 |
|
RU2748993C1 |
| CALPAIN MODULATORS AND THEIR THERAPEUTIC USE | 2017 |
|
RU2773288C2 |
| PYRIMIDOIMIDAZOLE COMPOUNDS USED AS DNA-RK INHIBITORS | 2020 |
|
RU2796163C1 |
| SUBSTITUTED TRICYCLIC COMPOUNDS AND METHOD OF APPLICATION | 2016 |
|
RU2744766C2 |
| PYRIDOPYRIMIDINE COMPOUNDS ACTING AS DOUBLE INHIBITORS OF mTORC 1/2 | 2018 |
|
RU2771201C2 |
| DERIVATIVE BASED ON DIHYDROPYRIMIDO-RING AS HBV INHIBITOR | 2015 |
|
RU2693897C2 |
| CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DESTRUCTION OF ANDROGEN RECEPTORS AND USE THEREOF | 2020 |
|
RU2825000C2 |
| 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE, METHOD FOR ITS OBTAINING AND ITS APPLICATION | 2019 |
|
RU2804127C2 |
| PYRROLIDINE DERIVATIVES AS PPAR AGONISTS | 2017 |
|
RU2711991C1 |
